BioLASCO Taiwan Co

BioLASCO Taiwan Co FCF Conversion

The FCF Conversion Rate (FCF/EBITDA) of BioLASCO Taiwan Co (6662.TWO) as of Oct 19, 2026 is 63.78 %. In the previous year, FCF Conversion Rate (FCF/EBITDA) was 2.11 % — a change of 2,916.16% (higher).

FCF Conversion

63.78 %

YoY

2,916.16%

Last updated:

FCF Conversion Rate (FCF/EBITDA) of BioLASCO Taiwan Co is 2025 63.78 % . FCF Conversion Rate (FCF/EBITDA) of BioLASCO Taiwan Co was 2024 2.11 % . It decreases by 2,916.16% higher compared to the previous year.

The BioLASCO Taiwan Co FCF Conversion history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

FCF Conversion
Date
FCF Conversion
Jan 1, 2018
134.71 TWD
Jan 1, 2019
229.81 TWD
Jan 1, 2020
-65.11 TWD
Jan 1, 2021
147.25 TWD
Jan 1, 2022
95.53 TWD
Jan 1, 2023
55.95 TWD
Jan 1, 2024
2.11 TWD
Jan 1, 2025
63.78 TWD
The BioLASCO Taiwan Co FCF Conversion history
YEARFCF ConversionYoY
63.78 %+2,916.16%
2.11 %-96.22%
55.95 %-41.43%
95.53 %-35.12%
147.25 %-326.16%
-65.11 %-128.33%
229.81 %+70.60%
134.71 %-345.39%
-54.89 %-146.50%
118.06 %+0.87%
117.04 %+10,076.06%
1.15 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

BioLASCO Taiwan Co Stock analysis

What does BioLASCO Taiwan Co do? BioLASCO Taiwan Co Ltd operates in the Health Care sector, specializing in Life Sciences Tools & Services. Based in Taipei City, the company produces and sells specific pathogen-free experimental mice and rats, including inbred strains and immune-deficient models. It also offers related equipment for feeding, supplies, and testing platforms, alongside life science research and pharmaceutical development services. Listed on 4 January 2018, BioLASCO Taiwan focuses on supporting biomedical research and drug development. BioLASCO Taiwan Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about BioLASCO Taiwan Co stock

FCF Conversion Rate (FCF/EBITDA) of BioLASCO Taiwan Co is 63.78 % in 2025.

FCF Conversion Rate (FCF/EBITDA) of BioLASCO Taiwan Co changed from 2.11 % to 63.78 %, representing a 2,916.16% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of FCF Conversion Rate (FCF/EBITDA) BioLASCO Taiwan Co since 2006 – with annual values, charts, and detailed analysis.

FCF conversion measures how effectively EBITDA converts to free cash flow. Higher conversion indicates efficient capital allocation and low maintenance costs.

A 'good' varies by industry and company stage. On Eulerpool, you can compare FCF Conversion Rate (FCF/EBITDA)'s BioLASCO Taiwan Co with sector peers and the industry average to assess whether it is attractive.

To evaluate FCF Conversion Rate (FCF/EBITDA)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for FCF Conversion Rate (FCF/EBITDA).

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Cash Flow — BioLASCO Taiwan Co

Operating Cash FlowCapital ExpendituresFree Cash FlowFCF per ShareDividends PaidShare BuybacksInvesting Cash FlowFinancing Cash FlowCapEx / RevenueCash Flow per ShareStock-Based CompensationChange in Working CapitalAcquisitions (Net)Net Change in CashCapEx/OCFFCF/Net IncomeFCF ConversionCash ConversionTotal Shareholder PayoutCapEx/D&A

All Key Metrics — BioLASCO Taiwan Co